comparemela.com

Latest Breaking News On - Tianjin municipal science - Page 1 : comparemela.com

Highly Selective Bailout GPI May Benefit in STEMI-PCI Subgroup

Frontiers | GPX7 Is Targeted by miR-29b and GPX7 Knockdown Enhances Ferroptosis Induced by Erastin in Glioma

Background Glioma is a lethal primary tumor of central nervous system. Ferroptosis is a newly identified form of necrotic cell death. Triggering ferroptosis has shown potential to eliminate aggressive tumors. GPX7, a member of glutathione peroxidase family (GPXs), has been described to participate in oxidative stress and tumorigenesis. However, the biological functions of GPX7 in glioma are still unknown. Methods Bioinformatics method was used to assess the prognostic role of GPX7 in glioma. CCK8, wound healing, transwell and cell apoptosis assays were performed to explore the functions of GPX7 in glioma cells. In vivo experiment was also conducted to confirm in vitro findings. Ferroptosis-related assays were carried out to investigate the association between GPX7 and ferroptosis in glioma. Results GPX7 was aberrantly expressed in glioma and higher expression of GPX7 was correlated with adverse outcomes. GPX7 silencing enhanced ferroptosis-related oxidative stress in glioma cells and t

天津这家企业再获国内之最!4款干细胞药物预计2025年上市 _ 东方财富网

天津这家企业再获国内之最!4款干细胞药物预计2025年上市 _ 东方财富网
eastmoney.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eastmoney.com Daily Mail and Mail on Sunday newspapers.

生机集团 天津市普天惠生物科技有限公司-企业-农博数据中心

生机集团 天津市普天惠生物科技有限公司-企业-农博数据中心
aweb.com.cn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from aweb.com.cn Daily Mail and Mail on Sunday newspapers.

天津市万格尔生物工程有限公司-企业-农博数据中心

天津市万格尔生物工程有限公司-企业-农博数据中心
aweb.com.cn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from aweb.com.cn Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.